- Home
- AVDX vs KNSA Comparison
AVDX vs KNSA Comparison
Compare AVDX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- KNSA
- Stock Information
- Founded
- AVDX 2000
- KNSA 2015
- Country
- AVDX United States
- KNSA United Kingdom
- Employees
- AVDX N/A
- KNSA N/A
- Industry
- AVDX EDP Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- KNSA Health Care
- Exchange
- AVDX Nasdaq
- KNSA Nasdaq
- Market Cap
- AVDX 2.0B
- KNSA 1.9B
- IPO Year
- AVDX 2021
- KNSA 2018
- Fundamental
- Price
- AVDX $9.94
- KNSA $35.71
- Analyst Decision
- AVDX Hold
- KNSA Strong Buy
- Analyst Count
- AVDX 14
- KNSA 6
- Target Price
- AVDX $9.73
- KNSA $40.83
- AVG Volume (30 Days)
- AVDX 2.0M
- KNSA 439.9K
- Earning Date
- AVDX 11-05-2025
- KNSA 10-28-2025
- Dividend Yield
- AVDX N/A
- KNSA N/A
- EPS Growth
- AVDX N/A
- KNSA N/A
- EPS
- AVDX N/A
- KNSA 0.07
- Revenue
- AVDX $446,722,000.00
- KNSA $529,332,000.00
- Revenue This Year
- AVDX $5.58
- KNSA $37.21
- Revenue Next Year
- AVDX $9.73
- KNSA $11.99
- P/E Ratio
- AVDX N/A
- KNSA $539.78
- Revenue Growth
- AVDX 8.04
- KNSA 56.18
- 52 Week Low
- AVDX $6.61
- KNSA $17.82
- 52 Week High
- AVDX $11.68
- KNSA $35.82
- Technical
- Relative Strength Index (RSI)
- AVDX 71.77
- KNSA 72.49
- Support Level
- AVDX $9.89
- KNSA $33.25
- Resistance Level
- AVDX $9.95
- KNSA $34.16
- Average True Range (ATR)
- AVDX 0.02
- KNSA 0.83
- MACD
- AVDX -0.00
- KNSA 0.07
- Stochastic Oscillator
- AVDX 83.33
- KNSA 95.59
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.